BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Davies C, Bhattacharyya S. Cannabidiol as a potential treatment for psychosis. Ther Adv Psychopharmacol 2019;9:2045125319881916. [PMID: 31741731 DOI: 10.1177/2045125319881916] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Berlowitz I, García Torres E, Maake C, Wolf U, Martin-Soelch C. Indigenous-Amazonian Traditional Medicine's Usage of the Tobacco Plant: A Transdisciplinary Ethnopsychological Mixed-Methods Case Study. Plants (Basel) 2023;12. [PMID: 36679060 DOI: 10.3390/plants12020346] [Reference Citation Analysis]
2 Sinha JK, Sachdeva P, Ahmad F, Sarkar J, Izhar R, Rahman A, Ghosh S. Pharmacotherapy and Emerging Treatment Strategies for Schizophrenia. Cognizance of Schizophrenia:: A Profound Insight into the Psyche 2023. [DOI: 10.1007/978-981-19-7022-1_10] [Reference Citation Analysis]
3 Jain V, Behl T, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Meraya AM, Najmi A. Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson's Disease: A Novel and Futuristic Approach. Neurotox Res 2022. [PMID: 36567416 DOI: 10.1007/s12640-022-00619-y] [Reference Citation Analysis]
4 Sultan W, Mathew A, Brown MRD, Gálvez-flórez JF, Moreno-sanz G. Cannabis-Based Medicinal Products in the Management of Emotionally Unstable Personality Disorder (EUPD): A Narrative Review and Case Series. Brain Sciences 2022;12:1467. [DOI: 10.3390/brainsci12111467] [Reference Citation Analysis]
5 Ma L, Platnick S, Platnick H. Cannabidiol in Treatment of Autism Spectrum Disorder: A Case Study. Cureus 2022. [DOI: 10.7759/cureus.28442] [Reference Citation Analysis]
6 Sainz-Cort A, Jimenez-Garrido D, Muñoz-Marron E, Viejo-Sobera R, Heeroma J, Bouso JC. The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study. Cannabis Cannabinoid Res 2022. [PMID: 35881851 DOI: 10.1089/can.2022.0037] [Reference Citation Analysis]
7 Gunasekera B, Wilson R, O'Neill A, Blest-Hopley G, O'Daly O, Bhattacharyya S. Cannabidiol attenuates insular activity during motivational salience processing in patients with early psychosis. Psychol Med 2022;:1-10. [PMID: 35775365 DOI: 10.1017/S0033291722001672] [Reference Citation Analysis]
8 Saleem A, Qurat-Ul-Ain, Akhtar MF. Alternative Therapy of Psychosis: Potential Phytochemicals and Drug Targets in the Management of Schizophrenia. Front Pharmacol 2022;13:895668. [PMID: 35656298 DOI: 10.3389/fphar.2022.895668] [Reference Citation Analysis]
9 Trivedi MK, Mondal S, Gangwar M, Jana S. Effects of Cannabidiol Interactions with CYP2R1, CYP27B1, CYP24A1, and Vitamin D3 Receptors on Spatial Memory, Pain, Inflammation, and Aging in Vitamin D3 Deficiency Diet-Induced Rats. Cannabis Cannabinoid Res 2022. [PMID: 35443806 DOI: 10.1089/can.2021.0240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Umpierrez LS, Costa PA, Michelutti EA, Baracz SJ, Sauer M, Turner AJ, Everett NA, Arnold JC, Mcgregor IS, Cornish JL. Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology. [DOI: 10.1007/s00213-022-06119-3] [Reference Citation Analysis]
11 Zieglgänsberger W, Brenneisen R, Berthele A, Wotjak CT, Bandelow B, Tölle TR, Lutz B. Chronic Pain and the Endocannabinoid System: Smart Lipids – A Novel Therapeutic Option? Med Cannabis Cannabinoids. [DOI: 10.1159/000522432] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Morris G, Walder K, Berk M, Carvalho AF, Marx W, Bortolasci CC, Yung AR, Puri BK, Maes M. Intertwined associations between oxidative and nitrosative stress and endocannabinoid system pathways: Relevance for neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2022;114:110481. [PMID: 34826557 DOI: 10.1016/j.pnpbp.2021.110481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
13 Kirkland AE, Fadus MC, Gruber SA, Gray KM, Wilens TE, Squeglia LM. A scoping review of the use of cannabidiol in psychiatric disorders. Psychiatry Res 2022;308:114347. [PMID: 34952255 DOI: 10.1016/j.psychres.2021.114347] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
14 Schecter D, Cyr C. Choosing a Product, Route of Administration, Initial Dosage, Titration, Monitoring and Management of Adverse Effects. Cannabis and Cannabinoid-Based Medicines in Cancer Care 2022. [DOI: 10.1007/978-3-030-89918-9_7] [Reference Citation Analysis]
15 Dyck GJB, Maayah ZH, Eurich DT, Dyck JRB. Understanding the Potential Benefits of Cannabidiol for Patients With Schizophrenia: A Narrative Review. Schizophrenia Bulletin Open 2022;3. [DOI: 10.1093/schizbullopen/sgab053] [Reference Citation Analysis]
16 Lemon C, Thompson A. The Role of Psychopharmacology in Mental Health Prevention. Prevention in Mental Health 2022. [DOI: 10.1007/978-3-030-97906-5_3] [Reference Citation Analysis]
17 Zuccoli GS, Brandão-teles C, Vieira GM, Gomes FV, Crunfli F. Molecular Findings Guiding the Modulation of the Endocannabinoid System as a Potential Target to Treat Schizophrenia. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-3-030-97182-3_7] [Reference Citation Analysis]
18 Vilca-Melendez S, Uthaug MV, Griffin JL. 1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids? Front Psychiatry 2021;12:742856. [PMID: 34966300 DOI: 10.3389/fpsyt.2021.742856] [Reference Citation Analysis]
19 Bilge S, Ekici B. CBD-enriched cannabis for autism spectrum disorder: an experience of a single center in Turkey and reviews of the literature. J Cannabis Res 2021;3:53. [PMID: 34911567 DOI: 10.1186/s42238-021-00108-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Ukaegbu O, Smith J, Hall D, Frain T, Abbasian C. Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK. J Cannabis Res 2021;3:51. [PMID: 34906259 DOI: 10.1186/s42238-021-00104-x] [Reference Citation Analysis]
21 Brown E, Gao CX, Staveley H, Williams G, Farrelly S, Rickwood D, Telford N, Papanastasiou C, McGorry P, Thompson A. The clinical and functional outcomes of a large naturalistic cohort of young people accessing national early psychosis services. Aust N Z J Psychiatry 2021;:48674211061285. [PMID: 34845922 DOI: 10.1177/00048674211061285] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
22 Anderson CL, Carney PR. Cannabidiol - A new fixture in childhood neurology. Curr Opin Pharmacol 2021;61:142-6. [PMID: 34808574 DOI: 10.1016/j.coph.2021.10.002] [Reference Citation Analysis]
23 Greenwood LM, Broyd SJ, van Hell HH, Todd J, Jones A, Murray RM, Croft RJ, Michie PT, Solowij N. Acute effects of Δ9-tetrahydrocannabinol and cannabidiol on auditory mismatch negativity. Psychopharmacology (Berl) 2021. [PMID: 34719731 DOI: 10.1007/s00213-021-05997-3] [Reference Citation Analysis]
24 Hassan Almalki W. A study of abnormal cannabidiols system-mediated cardiovascular protection in disrupted gut/brain axis associated depression. J Biochem Mol Toxicol 2021;35:e22930. [PMID: 34676637 DOI: 10.1002/jbt.22930] [Reference Citation Analysis]
25 Kudahl B, Berg ME, Posselt CM, Nordentoft M, Hjorthøj C. Medical cannabis and cannabis-based medicine show both potential efficacy and potential harms: Cross-sectional comparison with controls on self-rated and interviewer-rated outcomes within the Danish pilot program on medical cannabis. Complement Ther Clin Pract 2021;45:101476. [PMID: 34425501 DOI: 10.1016/j.ctcp.2021.101476] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Gabaglio M, Zamberletti E, Manenti C, Parolaro D, Rubino T. Long-Term Consequences of Adolescent Exposure to THC-Rich/CBD-Poor and CBD-Rich/THC-Poor Combinations: A Comparison with Pure THC Treatment in Female Rats. Int J Mol Sci 2021;22:8899. [PMID: 34445602 DOI: 10.3390/ijms22168899] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
27 Hassan Almalki W, Alzahrani A, Mahmoud El-Daly ME, Faissal Fadel Ahmed AH. A molecular explanation of cardiovascular protection through abnormal cannabidiol: Involving the dysfunctional β-adrenergic and ATP-sensitive K+ channel activity in cardiovascular compromised preterm infants. J Biochem Mol Toxicol 2021;:e22849. [PMID: 34309957 DOI: 10.1002/jbt.22849] [Reference Citation Analysis]
28 Ahmed S, Roth RM, Stanciu CN, Brunette MF. The Impact of THC and CBD in Schizophrenia: A Systematic Review. Front Psychiatry 2021;12:694394. [PMID: 34366924 DOI: 10.3389/fpsyt.2021.694394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
29 Paul S, Bhattacharyya S. Cannabis use-related working memory deficit mediated by lower left hippocampal volume. Addict Biol 2021;26:e12984. [PMID: 33155343 DOI: 10.1111/adb.12984] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Athanassiou M, Dumais A, Gnanhoue G, Abdel-Baki A, Jutras-Aswad D, Potvin S. A systematic review of longitudinal studies investigating the impact of cannabis use in patients with psychotic disorders. Expert Rev Neurother 2021;21:779-91. [PMID: 34120548 DOI: 10.1080/14737175.2021.1942845] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
31 Seillier A. The endocannabinoid system as a therapeutic target for schizophrenia: Failures and potentials. Neurosci Lett 2021;759:136064. [PMID: 34146641 DOI: 10.1016/j.neulet.2021.136064] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Thériault RK, St-Denis M, Hewitt T, Khokhar JY, Lalonde J, Perreault ML. Sex-Specific Cannabidiol- and Iloperidone-Induced Neuronal Activity Changes in an In Vitro MAM Model System of Schizophrenia. Int J Mol Sci 2021;22:5511. [PMID: 34073710 DOI: 10.3390/ijms22115511] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
33 Sadaka AH, Ozuna AG, Ortiz RJ, Kulkarni P, Johnson CT, Bradshaw HB, Cushing BS, Li AL, Hohmann AG, Ferris CF. Cannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice. J Transl Med 2021;19:220. [PMID: 34030718 DOI: 10.1186/s12967-021-02891-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
34 Pedrazzi JFC, Sales AJ, Guimarães FS, Joca SRL, Crippa JAS, Del Bel E. Cannabidiol prevents disruptions in sensorimotor gating induced by psychotomimetic drugs that last for 24-h with probable involvement of epigenetic changes in the ventral striatum. Prog Neuropsychopharmacol Biol Psychiatry 2021;111:110352. [PMID: 34015384 DOI: 10.1016/j.pnpbp.2021.110352] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
35 Morie KP, Potenza MN. A Mini-Review of Relationships Between Cannabis Use and Neural Foundations of Reward Processing, Inhibitory Control and Working Memory. Front Psychiatry 2021;12:657371. [PMID: 33967859 DOI: 10.3389/fpsyt.2021.657371] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
36 Wainberg M, Jacobs GR, di Forti M, Tripathy SJ. Cannabis, schizophrenia genetic risk, and psychotic experiences: a cross-sectional study of 109,308 participants from the UK Biobank. Transl Psychiatry 2021;11:211. [PMID: 33837184 DOI: 10.1038/s41398-021-01330-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
37 Kraft K, Schmidt M. Ist Cannabidiol ein Lebensmittel oder ein Arzneimittel? Zeitschrift für Phytotherapie 2021;42:82-94. [DOI: 10.1055/a-1336-6273] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Bartoli F, Riboldi I, Bachi B, Calabrese A, Moretti F, Crocamo C, Carrà G. Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review. J Clin Med 2021;10:1303. [PMID: 33810033 DOI: 10.3390/jcm10061303] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Moltke J, Hindocha C. Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 2021;3:5. [PMID: 33602344 DOI: 10.1186/s42238-021-00061-5] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
40 Arora NB, von Salm JL. Fall 2020 Proceedings of the Cannabis Chemistry Subdivision. ACS Chem Health Saf 2021;28:73-93. [DOI: 10.1021/acs.chas.0c00119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Colangeli R, Teskey GC, Di Giovanni G. Endocannabinoid-serotonin systems interaction in health and disease. Prog Brain Res 2021;259:83-134. [PMID: 33541682 DOI: 10.1016/bs.pbr.2021.01.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
42 Gunasekera B, Davies C, Martin-Santos R, Bhattacharyya S. The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of Δ9-Tetrahydrocannabinol and Cannabidiol. Biol Psychiatry Cogn Neurosci Neuroimaging 2021;6:636-45. [PMID: 33414100 DOI: 10.1016/j.bpsc.2020.10.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
43 Berlowitz I, Torres EG, Walt H, Wolf U, Maake C, Martin-Soelch C. "Tobacco Is the Chief Medicinal Plant in My Work": Therapeutic Uses of Tobacco in Peruvian Amazonian Medicine Exemplified by the Work of a Maestro Tabaquero. Front Pharmacol 2020;11:594591. [PMID: 33117182 DOI: 10.3389/fphar.2020.594591] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
44 Hjorthøj C, Posselt CM, Baandrup L. Cannabidiol for cannabis use disorder: too high hopes? Lancet Psychiatry 2020;7:838-9. [PMID: 32949512 DOI: 10.1016/S2215-0366(20)30378-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
45 Fusar-Poli L, Cavone V, Tinacci S, Concas I, Petralia A, Signorelli MS, Díaz-Caneja CM, Aguglia E. Cannabinoids for People with ASD: A Systematic Review of Published and Ongoing Studies. Brain Sci 2020;10:E572. [PMID: 32825313 DOI: 10.3390/brainsci10090572] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 7.7] [Reference Citation Analysis]
46 Colizzi M, Ruggeri M, Bhattacharyya S. Unraveling the Intoxicating and Therapeutic Effects of Cannabis Ingredients on Psychosis and Cognition. Front Psychol 2020;11:833. [PMID: 32528345 DOI: 10.3389/fpsyg.2020.00833] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
47 Dos Santos RG, Guimarães FS, Crippa JAS, Hallak JEC, Rossi GN, Rocha JM, Zuardi AW. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials. Expert Opin Drug Metab Toxicol 2020;16:517-26. [PMID: 32271618 DOI: 10.1080/17425255.2020.1754793] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
48 Machado-de-Sousa JP, Crippa JAS, Hallak J. Proneness, urbanicity, trauma, and cannabis triggering psychotic states in large urban centers. Curr Opin Psychiatry 2020;33:250-4. [PMID: 32068568 DOI: 10.1097/YCO.0000000000000592] [Reference Citation Analysis]
49 Scheau C, Badarau IA, Mihai LG, Scheau AE, Costache DO, Constantin C, Calina D, Caruntu C, Costache RS, Caruntu A. Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules 2020;25:E652. [PMID: 32033005 DOI: 10.3390/molecules25030652] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 12.0] [Reference Citation Analysis]
50 Skalicka-woźniak K, Gertsch J. Antipsychotic natural products. Annual Reports in Medicinal Chemistry 2020. [DOI: 10.1016/bs.armc.2020.03.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]